Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile at single cell level of bulk liver allograft tissue isolated 12 months post-transplant in patients receiving regulatory dendritic cell therapy (STUDY) and reference standard-of-care patients (SOC)

ABSTRACT: Gene expression profile at single cell level of bulk liver allograft tissue isolated 12 months post-transplant in patients receiving regulatory dendritic cell therapy (STUDY) and reference standard-of-care patients (SOC)

PROVIDER: PRJNA902375 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22313879.fastq.gz	Fastqsanger.gz
	SRR22313880.fastq.gz	Fastqsanger.gz
	SRR22313881.fastq.gz	Fastqsanger.gz
	SRR22313882.fastq.gz	Fastqsanger.gz
	SRR22313883.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 17

Similar Datasets

Gene expression profile at single cell level of bulk liver allograft tissue isolated 12 months post-transplant in patients receiving regulatory dendritic cell therapy (STUDY) and reference standard-of-care patients (SOC)

Project description:Regulatory dendritic cell therapy has shown potential in modulating the effector immune response after liver transplant in precliical models . We used single cell RNA sequencing (scRNA-seq) to analyze the differences in immune cell landscape of liver allograft at 12 months post-transplant in patients infused with regulatory dendritic cell therapy compared to standard-of-care control patients.

2023-06-01 | GSE218121 | GEO

Cancer Patients Receiving Immune Therapy

Project description:Cancer Patients Receiving Immune Therapy

| PRJNA838058 | ENA

Cancer Patients Receiving Immune Therapy

Project description:Cancer Patients Receiving Immune Therapy

| PRJNA838059 | ENA

Symptom Clusters in Oncology Patients Receiving Chemotherapy

Project description:Symptom Clusters in Oncology Patients Receiving Chemotherapy

| PRJNA1199600 | ENA

Symptom Clusters in Oncology Patients Receiving Chemotherapy

Project description:Symptom Clusters in Oncology Patients Receiving Chemotherapy

| PRJNA1199601 | ENA

Australian Chronic Allograft Dysfunction II

Project description:The Australian Chronic Allograft Dysfunction (AUSCAD) study is an ongoing single centre cohort study at Westmead hospital in Australia. In this section of the study, we aimed to identify biomarkers for chronic allograft dysfunction in kidney transplant recipients. Our study recruited 136 patients, each having protocol renal allograft biopsies taken pre transplantation.

2024-04-05 | GSE261240 | GEO

Australian Chronic Allograft Dysfunction III

Project description:The Australian Chronic Allograft Dysfunction (AUSCAD) study is an ongoing single centre cohort study at Westmead hospital in Australia. In this section of the study, we aimed to identify biomarkers for allograft rejection in kidney transplant recipients, 3-months after their transplant. Our study recruited 123 patients, each having protocol renal allograft biopsies taken 3-months post transplantation.

2024-04-05 | GSE261892 | GEO

Transcriptome data of multiple sclerosis patients receiving fingolimod therapy

Project description:Transcriptome data of multiple sclerosis patients receiving fingolimod therapy

| PRJNA296075 | ENA

Whole blood transcriptomes of patients receiving digital subtraction angiography

Project description:Whole blood transcriptomes of patients receiving digital subtraction angiography

| PRJNA669857 | ENA

Proteomic analysis of renal biomarkers of kidney allograft fibrosis – a study in renal transplant patients

Project description:Renal transplantation is the preferred treatment of end stage renal disease, but allograft survival is limited by development of interstitial fibrosis and tubular atrophy in response to various stimuli. Much effort has been put into identifying new protein markers of fibrosis to support the diagnosis. In present work, we performed an in-depth quantitative proteomics analysis of allograft biopsies from 31 prevalent renal transplant patients and identified correlated the quantified proteins with the volume fraction of fibrosis as determined by a morphometric method. Linear regression analysis identified four proteins that were highly associated with the degree of interstitial fibrosis, namely Coagulation Factor XIII A chain (estimate 18.7, adjusted p<0.03), Uridine Phosphorylase 1 (estimate 19.4, adjusted p<0.001), Actin-related protein 2/3 subunit 2 (estimate 34.2, adjusted p<0.05) and Cytochrome C Oxidase Assembly Factor 6 homolog (estimate -44.9, adjusted p<0.002) even after multiple testing. Proteins that were negatively associated with fibrosis (p < 0.005) were primarily related to normal metabolic processes and respiration, whereas proteins that were positively associated with fibrosis (p < 0.005) were involved in catabolic processes, cytoskeleton organization and immune response. The identified proteins may be candidates for further validation with regards to renal fibrosis. The results support the notion that cytoskeleton organization and immune responses are prevalent processes in renal allograft fibrosis.

2020-05-26 | PXD017867 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data